Research programme: metabotropic glutamate receptor 5 modulators - Addex Therapeutics

Drug Profile

Research programme: metabotropic glutamate receptor 5 modulators - Addex Therapeutics

Alternative Names: ADX 47273; ADX 50938; ADX 63365; ADX63365 (mGluR5 PAMb); ADX63365 (mGluR5 positive allosteric modulator [PAM]); CDPPB; Metabotropic glutamate receptor-5 modulators - Addex; mGluR5 modulators - Addex

Latest Information Update: 14 Aug 2012

Price : $50

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Schizophrenia

Most Recent Events

  • 21 Mar 2012 Addex Pharmaceuticals is now called Addex Therapeutics
  • 27 Jul 2011 Research programme: metabotropic glutamate receptor 5 modulators is no longer licensed to Merck worldwide
  • 15 Mar 2010 Preclinical development is ongoing in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top